Engineered immune cells aim to stop blood cancer relapse
NCT ID NCT04180059
First seen Jan 28, 2026 · Last updated May 12, 2026 · Updated 14 times
Summary
This study tests a new treatment for people with blood cancer who have had a stem cell transplant. The treatment uses specially designed immune cells (T cells) that can recognize and kill cancer cells that share a specific marker (HLA-DPB1*04:01). The goal is to see if this cell infusion is safe and can prevent the cancer from coming back. Six adults will receive increasing doses of these cells to find the highest safe dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMATOLOGIC DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu de Nantes
RECRUITINGNantes, France
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.